Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

This study is testing whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy and radiation improves outcomes for people with advanced esophageal squamous cell cancer. It targets patients with locally advanced (stage IVA) or a small number of spread lesions (oligometastatic stage IVB) who have never received prior treatment. **You may be eligible if...** - You are 18–75 years old with confirmed esophageal squamous cell cancer at an advanced stage - You have at least one measurable lesion on imaging - You have never received any prior treatment for this cancer - Your major organs (blood, liver, kidneys) are functioning adequately - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have uncontrolled fluid around the lungs, heart, or abdomen - You are significantly malnourished (BMI below 18.5) and it cannot be corrected - You have significant gastrointestinal bleeding or deep ulcers - You have had prior allergy to any of the study drugs - You have an active autoimmune disease or are on immunosuppressants - You have active hepatitis B or C - You have serious heart problems (heart failure, recent heart attack, or uncontrolled arrhythmia) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.